Open AccessLong-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus–16/18 Vaccine in Four- to Six-year-old Girls
Author(s) -
Lan Lin,
Mercedes Macías Parra,
Victor Y Sierra,
Albino Salas Cespedes,
Maria Angelica Granados,
Adriana Luque,
Naveen Karkada,
Maria Mercedes Castrejon Alba,
L. Mazzotti,
Dorota Borys,
Frank Struyf
Publication year - 2019
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002437
Subject(s) - medicine , immunogenicity , vaccination , adverse effect , immunization , hpv vaccines , cohort , pediatrics , immunology , hpv infection , cervical cancer , antibody , cancer
The burden of human papillomavirus (HPV) diseases is high in Latin America. HPV vaccines licensed from 2006 onwards offer protection against most HPV-related cancers, especially when introduced into national immunization programs. Barriers to optimal vaccine uptake are, however, lowering the impact of adolescent HPV vaccination programs. Immunization of children might overcome these barriers and be a strategy of choice for some countries.